IM-19 is under clinical development by Beijing Immunochina Pharmaceuticals and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase II drugs for Primary Mediastinal B-Cell Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IM-19’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IM-19 is under development for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia, B-cell acute lymphocytic leukemia (B-ALL), relapsed or refractory non-Hodgkin's lymphoma, B-cell chronic lymphocytic leukemia (B-CLL), diffuse large b-cell lymphoma, follicular lymphoma, primary mediastinal b-cell lymphoma and mantle cell lymphoma. The drug candidate is administered intravenously. It is developed based on chimeric antigen receptor (CAR) T-cell technology.
Beijing Immunochina Pharmaceuticals overview
Beijing Immunochina Pharmaceuticals (Immunochina) develops chimeric antigen receptor (CAR-T) cell molecules for the treatment of cancer. Its pipeline products include IM19, a CAR-T drug targeting CD19 antigen treating B-lineage malignancies including acute B-cell lymphoblastic leukemia, chronic lymphocytic leukemia and non-Hodgkin’s lymphoma; IM21, a CAR-T drug that targets B cell mature antigen (BCMA) in multiple myeloma; IM23 targeting CD123 in acute myeloid leukemia (AML). Immunochina utilizes its proprietary CAR-T technology platform to develop novel CAR-T therapeutics. Immunochina is headquartered in Beijing, China.
For a complete picture of IM-19’s drug-specific PTSR and LoA scores, buy the report here.